MNG887
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.324
- MYC_TARGETS_V2+0.218
- OXIDATIVE_PHOSPHORYLATION+0.170
- SPERMATOGENESIS+0.135
- E2F_TARGETS+0.087
- KRAS_SIGNALING_DN+0.076
- UV_RESPONSE_UP+0.046
- KRAS_SIGNALING_UP+0.041
- G2M_CHECKPOINT+0.035
- HEDGEHOG_SIGNALING+0.032
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.468
- INTERFERON_GAMMA_RESPONSE-0.423
- UV_RESPONSE_DN-0.403
- ALLOGRAFT_REJECTION-0.370
- MITOTIC_SPINDLE-0.366
- TNFA_SIGNALING_VIA_NFKB-0.363
- IL6_JAK_STAT3_SIGNALING-0.352
- INFLAMMATORY_RESPONSE-0.327
- TGF_BETA_SIGNALING-0.312
- PROTEIN_SECRETION-0.303
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 264656b8-d45c-4f5c-a431-366c566296fe | — | — | 0.886 |
| 2 | TCGA-KU-A66S-01A-21R-A30B-07 | — | — | 0.871 |
| 3 | TCGA-E5-A4U1-01A-11R-A31N-07 | — | — | 0.863 |
| 4 | SRR10900563 | — | — | 0.857 |
| 5 | SRR650150 | — | — | 0.853 |
| 6 | TCGA-DK-AA75-01A-11R-A39I-07 | — | — | 0.853 |
| 7 | SRR1797291 | — | cohortSC | 0.851 |
| 8 | TCGA-KQ-A41O-01A-12R-A352-07 | — | — | 0.851 |
| 9 | SAMN03290928 | — | — | 0.847 |
| 10 | MNG604 | — | — | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.324 | Cobimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.218 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.135 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.087 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.076 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.046 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.041 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.035 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.032 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.023 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.005 | Inavolisib | — uncovered |